Rakovina Therapeutics Presents Preclinical Data on novel kt-3000 Series Drug Candidates at JCA-AACR Precision Medicine International Conference

Vancouver, British Columbia, CANADA


VANCOUVER, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, today announced that the company has presented data from pre-clinical research with its novel kt-3000 series drug candidates at the inaugural JCA-AACR Precision Medicine Conference, which was held virtually on September 10-12, 2021 (US) and September 11-13 (Japan).

Rakovina Therapeutics presented data in a video presentation entitled In Vitro Activity of Novel Dual PARP-HDAC Inhibitors. The Company’s novel kt-3000 series is a dual inhibitor of poly (ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC). Publications to date have shown potential synergy between PARP inhibitors and HDAC inhibitors and the combination has been shown to sensitize PARP-inhibitor resistant cells to treatment in vitro. While the concept has demonstrated promise in the laboratory, translation to a clinical setting has proved challenging. In patients, combination treatment often requires sequential administration due to overlapping toxicities and differing pharmacokinetics, severely limiting treatment options.

The kt-3000 series are novel drug candidates that combine PARP and HDAC inhibition into a single molecule, which may provide a more viable approach to clinical benefit that might overcome clinical resistance to PARP inhibition and potentially expand the utility of PARP inhibitors beyond HR-deficient disease.

Data presented at the conference show that select kt-3000 series compounds exhibit strong inhibition of both PARP and HDAC as a single molecule. Activity at each target is comparable to FDA-approved single-target PARP or HDAC inhibitors.

“We are pleased with the progress in the development of the kt-3000 series to date. Importantly, these data demonstrate activity of kt-3000 series compounds in both BRCA-wild type and BRCA-mutant cell lines suggesting the potential to address unmet needs in the treatment of HR-proficient cancers with dysregulation of histone deacetylation,” said Prof. Mads Daugaard, president and chief scientific officer of Rakovina Therapeutics. “We look forward to continuing to report our progress at upcoming scientific meetings.”

About Rakovina Therapeutics Inc.

Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com.

Additional Information

The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding forward-looking statements:

This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedar.com.

Contact:

Rakovina Therapeutics Inc.
David Hyman
Chief Financial Officer
Email: info@rakovinatherapeutics.com

Investor Relations Contact
IR@rakovinatherapeutics.com

Media Contact
MEDIA@rakovinatherapeutics.com